**BACKGROUND**

- **COM701** is a novel fusion protein with checkpoint inhibitor activity (PD-1) and monomeric IgG1 Fc fragment.
- **PVRIG** is a member of the DNAM/TIGIT signaling axis regulating the activity of T/NK cells.

**METHODS**

- **Study design**: Phase 1a, dose escalation in patients with refractory disease or those for whom current treatment options are not available.
- **Key eligibility criteria**:
  - Untreated or symptomatic central nervous system metastasis
  - MM patients with refractory disease

**RESULTS**

- **No dose-limiting toxicities** reported.
- **No treatment discontinuation** due to adverse events.
- **2/3 pts** with CRC showed confirmed SD in 2/3 pts with CRC.

**CONCLUSIONS**

- **COM701** in combination with ICI may have potential for further investigation.
- **Future directions**: Further study in patients with refractory disease, previously treated with ICI.

**REFERENCES**

2. Tutt A, Cadril C, et al. PD-1 blockade in patients with various tumor types receiving nivolumab (anti-PD-1 monotherapy) and B (COM701 in combination with nivolumab) - poster P421 at this scientific conference.